Retmarker’s activities in the field of retinal diseases are detailed in a recent interview published in the OpticaPRO (issue 172) and OfetalPRO (issue 38) magazines.
The interview covers Retmarker's beginnings and our current offering, detailing the respective advantages for both general population and vision professionals.
Please find the full Press Release here (in Portuguese).
Professor Cunha-Vaz has been awarded at the Euretina 2016 for his prolific career. In the Euretina 2016 edition in Copenhagen, Professor Cunha-Vaz, founder and leader of our research partner AIBILI, was recognized for a career devoted to promoting innovation in Ophthalmology healthcare. In particular his research has moved forwarded clinical knowledge in the fields of Diabetic Retinopathy (DR) and Age-Related Macular Degeneration (AMD).
Professor Cunha-Vaz devoted his award receiving lecture to the alterations of the blood-retinal barrier (BRB) and how they play a crucial role in the development of retinal diseases such as the aforementioned DR and AMD. The lecture highlighted that Clinical evaluation of the BRB has evolved greatly over the past few decades, moving from earlier invasive techniques such as fluorescein angiography, vitreous fluorophotometry and retinal leakage analysis to more recent non-invasive methods such as optical coherence tomography leakage (OCT-L) measurement and quantification of extracellular space of the retina.
Please find more details here.
We are extremely excited to report that our automated retinal image analysis technology, developed over 10 years, has just received independent scientific confirmation of its huge global potential in the fight against Diabetic Retinopathy from a large-scale, UK study led by researchers from the prestigious Moorfields Eye Hospital in London.
The study’s team of researchers qualified all of the available technologies that met their eligibility criteria before submitting them for independent evaluation. Retmarker was the only European technology to be approved by the study based on its adequate sensitivity for detecting referable retinopathy in a high-volume clinical setting when compared with existing quality-assured, real-world methods that rely on human graders. Additionally, Retmarker showed adequate specificity that qualifies it as a more cost-effective alternative.